2019 yılında biofarmada dünya lisans anlaşmalarının ilk on beşinin toplam tutarı 41 Milyar USD ye ulaştı.
2019 will likely go down as a landmark year for biopharma partnering, at least when looking at the sums involved. Our rundown of the 15 largest licensing deals reveals a total value of $41.1 billion. Perhaps more significantly, more than $8.5 billion of that was paid upfront.
The figures come against a backdrop of plentiful levels of venture capital going into the sector—a pullback on 2018’s record levels, but still healthy—as well as a solid year for initial public offerings and acquisitions. The overall picture suggests that there is plenty of investment cash around for biopharma drug developers.
It’s also notable that more than half the total value came from the top 5 deals, headlined by AstraZeneca’s $6.9 billion tie-up with Daiichi Sankyo for HER2-targeting antibody-drug conjugate drug Enhertu and Gilead Sciences’ strategic alliance with Galapagos, which doubled its R&D capacity and also included the biggest upfront fee ($3.95 billion).
Gilead pledged the most to the pipeline-building activity, with three deals collectively worth almost $10 billion—with around $4 billion of that in early payments. Roche/Genentech stands at the head of the table with four deals overall, worth $8.55 billion but with less than $2 billion of that upfront.
